Joseph Kekst
Co-Founder @ Sporos Bioventures
New City, United States
Joseph Kekst is a Series A investor at Sporos Bioventures in New City focused on Biotechnology and Pharmaceutical. Joseph Kekst currently works as the co-founder of Sporos Bioventures. He previously worked at Brandeis University as a member of the board of advisors.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Joseph Kekst invests in
Stages Joseph Kekst invests in
Countries Joseph Kekst invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (50%)
- Pharmaceutical 2 (50%)
- Energy 1 (25%)
- FinTech 1 (25%)
- Medical 1 (25%)
Stage
- Series A 3 (75%)
- Seed 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Apis Point Energy
|
Apis Point Energy provides innovative price stability and risk management solutions for fuel wholesalers, distributors, and commercial buyers. Its proprietary platform offers forward contracts with fixed prices, ceilings, or floors on physically delivered refined fuels and natural gas liquids (NGLs), enabling clients to effectively manage fuelcosts amid market volatility. Apis Point helps fuel distributors offer stable and competitive pricing to their customers, which enhances customer loyalty and supports longer-term commitments. The platform uses advanced analytics to provide real-time forecasting and strategic market insights, streamlining complex hedging processes so clients can focus on their core business of delivering energy. | $4.2M / Series A / Jun 09, 2025 | |
Nirogy Therapeutics
|
Nirogy Therapeutics is a biotechnology company developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncologyas well as autoimmune diseases. | $16.5M / Series A / Jan 26, 2021 | |
Immuneering
|
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. It has more than a decade of experience in translationalbioinformatics and generating insights into drug mechanisms of action and patient treatment responses. | Series A / Jan 22, 2020 | |
VidaFuel
|
VidaFuel is a dietitian-developed nutritional support company that solves dietary pain points, both in the clinical setting and at home. The company was founded in 2016 and is based in Nashville, Tennessee. | $1.1M / Seed / Sep 30, 2019 |
Co-Investors
About Sporos Bioventures
Sporos Bioventures is a biotechnology firm that focuses on oncology, fibrosis, inflammation, and autoimmune and infection therapeutics. For patients with cancer and immune diseases, Sporos is transforming knowledge into a new hope. Sporos' team of accomplished leaders identifies novel disease mechanisms and catalyzes the development ofbreakthrough medicines by leveraging our extensive network, strategic resources, and operational expertise.
Sporos Bioventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Cranberg
Co-Founder
|
|||
Amit Rakhit
Chief Executive Officer
|
|||
Dana Levy
Co-Founder
|
|||
Jeno Gyuris
Managing Partner, Chief Scientist
|
|||
|
Joseph Kekst
Co-Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Joseph Kekst invest in?
Joseph Kekst invests primarily in Biotechnology, Pharmaceutical and Energy startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Joseph Kekst?
Public channels for Joseph Kekst include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Joseph Kekst last invest?
The most recent investment recorded for Joseph Kekst closed in Jun 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
